Clinical trial
A Phase 1, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending, Multiple Oral Doses of SPD489 (Lisdexamfetamine Dimesylate) in Clinically Stable Adults With Schizophrenia
NCT01457339 is registered in ClinicalTrials.gov with Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending, Multiple Oral Doses of SPD489 (Lisdexamfetamine Dimesylate) in Clinically Stable Adults With Schizophrenia
- Lead sponsor
- Shire
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 21, 2011
- Completion date
- January 20, 2012
- Enrollment
- 31 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.